Researchers have found evidence that could help explain why some anemic CKD patients are resistant to treatment with erythropoiesis stimulating agents. Patients on high-dose ESA had significantly ...

Jula K. Inrig, MD Investigators believe elevated levels of endogenous soluble erythropoietin receptors may have a role. SAN DIEGO—Researchers have found evidence that could help explain why some ...

In a Japanese study, approximately 1 in 8 CKD patients with anemia failed to respond to darbepoetin alfa therapy. Specific factors may predict better initial response to darbepoetin alfa in patients ...

Please provide your email address to receive an email when new articles are posted on . Patients switched to oral vadadustat had hemoglobin levels similar to those on a long-acting ...

Only about a quarter of patients who have myelodysplastic syndrome (MDS) experienced hematologic improvement with erythropoiesis-stimulating agents (ESAs). Patients with lower-risk myelodysplastic ...